aTyr Pharma (LIFE) Tops Q3 EPS by 6c

aTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.68), $0.06 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $148 thousand versus the consensus estimate of $100 thousand.

“Throughout the third quarter, we remained focused on our clinical program for our lead therapeutic candidate, ATYR1923. We now have three active clinical trials as part of this program. Most notably, we have completed enrollment in our Phase 2 trial in COVID-19 patients with severe respiratory complications. We expect to report topline data from this study around the turn of the calendar year. In addition, amidst the ongoing pandemic, our pulmonary sarcoidosis trial sites have been reactivated to screen and dose patients and finish enrollment of the third and final cohort of our Phase 1b/2a study. Finally, our partner Kyorin Pharmaceutical is currently enrolling a Phase 1 study in healthy volunteers in Japan,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

“While our clinical operations have expanded, so too has our pipeline. We have selected an Investigational New Drug (IND) candidate from our Neuropilin-2 (NRP2) antibody program, ATYR2810. This antibody, which has generated compelling data in pre-clinical cancer models, will be evaluated for the potential treatment of certain aggressive tumors where NRP2 is implicated.”

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Eos Energy Enterprises (EOSE) Provides Business Update